• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

JAK2突变体（例如，JAK2V617F）及其作为骨髓增殖性肿瘤药物靶点的重要性。

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

作者信息

Gäbler Karoline, Behrmann Iris, Haan Claude

机构信息

Signal Transduction Laboratory; Life Sciences Research Unit; University of Luxembourg; Luxembourg.

出版信息

JAKSTAT. 2013 Jul 1;2(3):e25025. doi: 10.4161/jkst.25025. Epub 2013 May 14.

DOI:10.4161/jkst.25025
PMID:24069563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3772115/
Abstract

The Janus kinase 2 (JAK2) mutant V617F and other JAK mutants are found in patients with myeloproliferative neoplasms and leukemias. Due to their involvement in neoplasia and inflammatory disorders, Janus kinases are promising targets for kinase inhibitor therapy. Several small-molecule compounds are evaluated in clinical trials for myelofibrosis, and ruxolitinib (INCB018424, Jakafi®) was the first Janus kinase inhibitor to receive clinical approval. In this review we provide an overview of JAK2V617F signaling and its inhibition by small-molecule kinase inhibitors. In addition, myeloproliferative neoplasms are discussed regarding the role of JAK2V617F and other mutant proteins of possible relevance. We further give an overview about treatment options with special emphasis on possible combination therapies.

摘要

在骨髓增殖性肿瘤和白血病患者中发现了Janus激酶2（JAK2）突变体V617F及其他JAK突变体。由于Janus激酶参与肿瘤形成和炎症性疾病，它们是激酶抑制剂治疗的有前景的靶点。几种小分子化合物正在进行骨髓纤维化的临床试验评估，而鲁索替尼（INCB018424，Jakafi®）是首个获得临床批准的Janus激酶抑制剂。在本综述中，我们概述了JAK2V617F信号传导及其被小分子激酶抑制剂抑制的情况。此外，还讨论了骨髓增殖性肿瘤中JAK2V617F及其他可能相关突变蛋白的作用。我们还特别强调可能的联合治疗，对治疗选择进行了概述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b15/3772115/07e64db5530b/jkst-2-e25025-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b15/3772115/280330ee58f3/jkst-2-e25025-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b15/3772115/19ebf665fd78/jkst-2-e25025-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b15/3772115/07e64db5530b/jkst-2-e25025-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b15/3772115/280330ee58f3/jkst-2-e25025-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b15/3772115/19ebf665fd78/jkst-2-e25025-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b15/3772115/07e64db5530b/jkst-2-e25025-g3.jpg

相似文献

1
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.JAK2突变体（例如，JAK2V617F）及其作为骨髓增殖性肿瘤药物靶点的重要性。
JAKSTAT. 2013 Jul 1;2(3):e25025. doi: 10.4161/jkst.25025. Epub 2013 May 14.
2
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].[JAK2V617F突变在慢性骨髓增殖性肿瘤患者中的意义]
Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.
3
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.选择性 JAK1/2 抑制剂 INCB018424 的临床前特征：治疗骨髓增生性肿瘤的治疗意义。
Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3.
4
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.用于治疗骨髓增殖性肿瘤的Janus激酶2抑制剂的研发与应用
Hematol Oncol Clin North Am. 2017 Aug;31(4):613-626. doi: 10.1016/j.hoc.2017.04.002. Epub 2017 May 17.
5
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
6
A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.一项关于Janus激酶2（JAK2）抑制剂甘托替尼（LY2784544）用于原发性骨髓纤维化、真性红细胞增多症和原发性血小板增多症患者的1期研究。
Leuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31.
7
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.用于治疗肿瘤性疾病和炎症性疾病的Janus激酶（JAK）抑制剂。
Pharmacol Res. 2022 Sep;183:106362. doi: 10.1016/j.phrs.2022.106362. Epub 2022 Jul 22.
8
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.骨髓增殖性疾病中细胞因子信号传导抑制因子3基因（SOCS3）的甲基化
Haematologica. 2008 Nov;93(11):1635-44. doi: 10.3324/haematol.13043. Epub 2008 Sep 24.
9
JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.JAK2 rs10974944 与越南人群中 V617F 阳性和阴性骨髓增殖性肿瘤均相关：一个潜在的遗传标志物。
Mol Genet Genomic Med. 2022 Oct;10(10):e2044. doi: 10.1002/mgg3.2044. Epub 2022 Aug 22.
10
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.INCB018424，一种 JAK1 和 JAK2 抑制剂，在骨髓纤维化中的安全性和疗效。
N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.

引用本文的文献

1
Innovative strategies for mitochondrial dysfunction in myeloproliferative neoplasms a step toward precision medicine.骨髓增殖性肿瘤中线粒体功能障碍的创新策略：迈向精准医学的一步
Ann Med Surg (Lond). 2025 Aug 19;87(9):5557-5568. doi: 10.1097/MS9.0000000000003365. eCollection 2025 Sep.
2
Myeloproliferative neoplasms complicated with β-thalassemia: Two case report.骨髓增殖性肿瘤合并β地中海贫血：两例报告。
World J Clin Cases. 2022 Oct 16;10(29):10655-10662. doi: 10.12998/wjcc.v10.i29.10655.
3
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2-induced myeloproliferative neoplasms.

本文引用的文献

1
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.JAK-STAT 通路在血液系统恶性肿瘤中的失调及 JAK 抑制剂的临床应用。
Biomark Res. 2013 Jan 16;1(1):5. doi: 10.1186/2050-7771-1-5.
2
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.口服多聚去乙酰化酶抑制剂帕比司他治疗原发性骨髓纤维化、特发性血小板增多症后和真性红细胞增多症后骨髓纤维化的 II 期临床试验。
Br J Haematol. 2013 Aug;162(3):326-35. doi: 10.1111/bjh.12384. Epub 2013 May 23.
3
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
马来酸氟罗替尼的临床前研究，一种新型的 JAK2/FLT3 抑制剂，用于治疗 JAK2 诱导的骨髓增生性肿瘤。
Blood Cancer J. 2022 Mar 7;12(3):37. doi: 10.1038/s41408-022-00628-2.
4
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.小分子抑制去泛素化酶 JOSD1 作为一种新型靶向治疗突变 JAK2 的白血病的策略。
Leukemia. 2022 Jan;36(1):210-220. doi: 10.1038/s41375-021-01336-9. Epub 2021 Jul 29.
5
SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.SENP1 介导的 JAK2 的去 SUMOylation 调节其激酶活性和铂类药物耐药性。
Cell Death Dis. 2021 Apr 1;12(4):341. doi: 10.1038/s41419-021-03635-6.
6
Givinostat: an emerging treatment for polycythemia vera.吉维司他：真性红细胞增多症的一种新兴疗法。
Expert Opin Investig Drugs. 2020 Jun;29(6):525-536. doi: 10.1080/13543784.2020.1761323. Epub 2020 Jul 21.
7
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2-positive myeloproliferative neoplasm cells.NT157 具有抗肿瘤作用，并抑制 JAK2 阳性骨髓增殖性肿瘤细胞中的 IRS1/2 和 STAT3/5。
Signal Transduct Target Ther. 2020 Jan 24;5(1):5. doi: 10.1038/s41392-019-0102-5.
8
Mutation Is Associated with STAT3 Activation in CD30 ALK ALCL.在CD30 ALK ALCL中，突变与STAT3激活相关。
Cancers (Basel). 2020 Mar 16;12(3):702. doi: 10.3390/cancers12030702.
9
Understanding the structural features of JAK2 inhibitors: a combined 3D-QSAR, DFT and molecular dynamics study.理解 JAK2 抑制剂的结构特征：三维定量构效关系、密度泛函理论和分子动力学的综合研究。
Mol Divers. 2019 Nov;23(4):845-874. doi: 10.1007/s11030-018-09913-4. Epub 2019 Jan 7.
10
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.致癌激活 STAT3 通路驱动自然杀伤/T 细胞淋巴瘤中 PD-L1 的表达。
Blood. 2018 Sep 13;132(11):1146-1158. doi: 10.1182/blood-2018-01-829424. Epub 2018 Jul 27.
芦可替尼在各患者亚组中的临床获益：一项安慰剂对照、III 期研究中对骨髓纤维化患者的分析。
Br J Haematol. 2013 May;161(4):508-16. doi: 10.1111/bjh.12274. Epub 2013 Mar 11.
4
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.芦可替尼治疗对 COMFORT-I 研究中骨髓纤维化相关症状和其他患者报告结局的影响：一项随机、双盲、安慰剂对照试验。
J Clin Oncol. 2013 Apr 1;31(10):1285-92. doi: 10.1200/JCO.2012.44.4489. Epub 2013 Feb 19.
5
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.mTOR 抑制剂单独使用和与 JAK2 抑制剂联合使用能有效抑制骨髓增殖性肿瘤细胞。
PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826. Epub 2013 Jan 31.
6
JAK inhibitors: beyond spleen and symptoms?JAK抑制剂：超越脾脏和症状？
Haematologica. 2013 Feb;98(2):160-2. doi: 10.3324/haematol.2012.083543.
7
Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.CEP701 抑制 Jak2V617F 表达细胞中的 Janus 和 Aurora 激酶的协同作用。
J Cell Mol Med. 2013 Feb;17(2):265-76. doi: 10.1111/jcmm.12005. Epub 2013 Jan 10.
8
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?慢性炎症作为原发性血小板增多症、真性红细胞增多症和骨髓纤维化中突变的促进因素。一种人类炎症模型与癌症发展有关？
Leuk Res. 2013 Feb;37(2):214-20. doi: 10.1016/j.leukres.2012.10.020. Epub 2012 Nov 20.
9
Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.评估真性红细胞增多症和原发性血小板增多症患者的白细胞介素-23 血浆水平。
Cell Immunol. 2012 Jul-Aug;278(1-2):91-4. doi: 10.1016/j.cellimm.2012.07.003. Epub 2012 Aug 1.
10
Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.甲基化组谱分析揭示了骨髓增殖性肿瘤表型和突变亚群的明显改变。
Cancer Res. 2013 Feb 1;73(3):1076-85. doi: 10.1158/0008-5472.CAN-12-0735. Epub 2012 Oct 11.